Latest Breaking News On - டெக்சாஸ் இன்க் - Page 5 : comparemela.com

The candidates are:  MYCO – 001: a form of pure psilocybin derived from natural fungal sources, targeted to be used at mid-to-late-stage clinical trials. MYCO – 002: an empathogen with similar effects to MDMA that could have an improved safety profile. MYCO – 003: a psilocybin-based formula that could diminish the possibility of bad experiences by reducing patient anxiety. MYCO – 004: a hallucinogen delivered transdermally, offering precision dosing and long-term compound stability. The claims presented for these compounds need to be proven in clinical trials and via further research. “By increasing the complexity of these compounds, we are increasing layers of patents applied, which in turn, also adds pharmaceutical value to the drug candidates,” said Joshua Bartch, co-founder and CEO of Mydecine.

United statesTimothy koScott wienerJoshua bartchKelsey ramsdenCalifornia psychedelics decriminalization bill passes senate committeeHalugen life sciences incSenate health committeeEntheon biomedical corpAtai life sciencesMydecine innovations group pinkSenate public safety committee of the californiaCore one labs incHealth canadaCure health incKetamine infusions centers of texas inc